FINWIRES · TerminalLIVE
FINWIRES

Elevra Lithium Ends Waratah Deal, Secures Full Moblan Offtake Control

By

Elevra Lithium (ASX:ELV) said it has purchased and terminated a spodumene concentrate offtake agreement previously granted to an investment vehicle managed by Waratah Capital Advisors in relation to the Moblan lithium project, according to a Tuesday filing with the Australian bourse.

Moblan is 60% owned by Elevra and 40% by Investissement Quebec.

The deal eliminates a life-of-mine obligation that previously allowed Waratah to buy 10% of the company's production share at a 5% discount to market prices, per the filing.

The company will issue Waratah $5 million in ordinary shares at AU$12.20 apiece and $500,000 in options at a 50% premium, with the options exercisable 120 days after closing on Tuesday and expiring three years thereafter, in exchange for terminating the agreement, the filing said.

The repurchase strengthens the company's position at Moblan by eliminating a discounted long-term sales commitment and giving it full control of offtake, increasing flexibility for supply and financing arrangements, the filing added.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH